---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-018972"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:34:22.916414+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva Pharmaceuticals enters into ATM sales agreement for up to $50M common stock offering

## Summary
- On May 30, 2025, Reviva entered an ATM agreement with B. Riley Securities and Alliance Global Partners to sell up to $50M of common stock.
- Sales will be made through Nasdaq as an 'at the market offering' under Rule 415; agents receive 3% commission.
- Shares issued under effective shelf registration statement (Form S-3 filed Feb 2024).
- No obligation for agents to sell any specific amount; they use commercially reasonable efforts based on company instructions.

## SEC filing metadata
- accession: 0001437749-25-018972
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925018972/0001437749-25-018972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925018972/rvph20250513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-018972
- JSON: https://secwatch.observer/filing/0001437749-25-018972.json
- Plain text: https://secwatch.observer/filing/0001437749-25-018972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.